Immunocore Holdings: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
Analyst Patrick Trucchio from H.C. Wainwright has reiterated a Buy rating for Immunocore Holdings, maintaining a price target of $100. The strong Q3 performance, particularly from KIMMTRAK, and strategic advancements in clinical trials support this rating. Immunocore's solid financial position enhances its growth potential. Oppenheimer also supports a Buy rating with a price target of $86.
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Immunocore Holdings. The associated price target remains the same with $100.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Immunocore Holdings’ strong performance and potential for future growth. The company reported impressive third-quarter 2025 net product revenue, driven by the continued success of KIMMTRAK, particularly in the U.S. and Europe. KIMMTRAK’s role as the standard of care for metastatic uveal melanoma and its expansion into new markets underscore its robust commercial potential.
Additionally, Immunocore’s strategic advancements in clinical trials, such as the dose selection for brenetafusp in a key Phase 3 trial, demonstrate significant progress in their oncology pipeline. The company’s strong financial position, with substantial liquidity, further supports its ability to execute on its growth strategies. Overall, these elements collectively reinforce Trucchio’s confidence in Immunocore’s leadership in the bispecific T cell receptor space and justify the Buy rating with a $100 price target.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $86.00 price target.
